Side-by-Side Comparison
| Metric | Alteogen | Synaffix |
|---|---|---|
| Founded | ||
| Founded | 2008 older | 2014 |
| Headquarters | ||
| Headquarters | Korea South | Oss, The Netherlands |
| Employees | ||
| Employees | 44 | 63 larger |
| Industry | ||
| Industry | Pharmaceutical | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series A | Acquired |
| Total Funding | ||
| Total Funding | Not tracked yet | $100.00M |
| Funding Rounds | ||
| Funding Rounds | Not tracked yet | 3 |
| Services | ||
| Services | Development of enhanced biosimilar products, Research and development of antibody drug conjugates (ADC), Implementation of proprietary technologies like NexP™ and NexMab™, Sustainable and socially responsible business practices | ADC Platform Licensing, Bispecific Antibody Development, Targeted Therapy Development, Out-licensing Technology for Cancer Therapeutics |
| Target Customers | ||
| Target Customers | Healthcare providers, Pharmaceutical companies, Medical researchers, ESG-focused investors | Pharmaceutical Companies, Biotechnology Firms, Oncology Researchers, Strategic Partners in Therapeutics |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Hybrozyme Technology, Human Hyaluronidase, Subcutaneous Injection, NexP Fusion Technology, Long-acting Biologics, Biobetters, NexMab ADC Technology, Antibody-Drug Conjugate, Cancer Therapeutics, Monoclonal Antibody Biosimilars, High-expression Cell Lines, Biologics Development, Therapeutic Proteins, Strategic Alliances | Antibody-Drug Conjugates, ADC Technology Platform, Licensed Partnerships, Biotech Innovation, Clinical-Stage Development, Enzymatic Glycan Modification, Metal-Free Click Chemistry, Site-Specific Conjugation, Cancer Therapeutics, Immune Cell Engagers, Targeted Gene Therapy, Bispecific Antibodies, Patent Portfolio, Phase 1 Clinical Trials, High Growth Market Segments |
| Website | ||
| Website | alteogen.com | synaffix.com |
About Alteogen
Alteogen, a leading biopharmaceutical company founded in 2008, is listed on the KOSDAQ stock exchange (KRX:196170). Based in South Korea, it is reshaping the future of medical treatments with a suite of proprietary platform technologies designed to enhance the efficacy and longevity of biologic medi...
About Synaffix
Synaffix, a Lonza Company, is a pioneering biotech firm founded in 2014 and headquartered in The Netherlands. It boasts a proprietary, clinical-stage technology platform focused on antibody-drug conjugates (ADCs), renowned for optimizing safety and efficacy. The platform's value is underscored by m...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Alteogen and Synaffix — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Alteogen and Synaffix — by email.
Frequently Asked Questions
Compare Alteogen with someone else
Start typing a company name or domain.